{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,14]],"date-time":"2026-04-14T16:50:20Z","timestamp":1776185420894,"version":"3.50.1"},"reference-count":43,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2023,9,22]],"date-time":"2023-09-22T00:00:00Z","timestamp":1695340800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Neurol."],"abstract":"<jats:sec><jats:title>Objective<\/jats:title><jats:p>This study aimed to evaluate the progression of clinical and preclinical trials in Charcot-Marie-Tooth (CMT) disorders.<\/jats:p><\/jats:sec><jats:sec><jats:title>Background<\/jats:title><jats:p>CMT has historically been managed symptomatically and with genetic counseling. The evolution of molecular and pathologic understanding holds a therapeutic promise in gene-targeted therapies.<\/jats:p><\/jats:sec><jats:sec><jats:title>Methods<\/jats:title><jats:p><jats:ext-link>ClinicalTrials.gov<\/jats:ext-link> from December 1999 to June 2022 was data extracted for CMT with preclinical animal gene therapy trials also reviewed by PubMed search.<\/jats:p><\/jats:sec><jats:sec><jats:title>Results<\/jats:title><jats:p>The number of active trials was 1 in 1999 and 286 in 2022. Academic settings accounted for 91% and pharmaceutical companies 9%. Of the pharmaceutical and academic trials, 38% and 28%, respectively, were controlled, randomized, and double-blinded. Thirty-two countries participated: the United States accounted for 26% (75\/286). In total, 86% of the trials were classified as therapeutic: 50% procedural (21% wrist\/elbow surgery; 22% shock wave and hydrodissection therapy), 23% investigational drugs, 15% devices, and 11% physical therapy. Sixty-seven therapeutic trials (49%) were designated phases 1\u20132 and 51% phases 3\u20134. The remaining 14% represent non-therapeutic trials: diagnostic testing (3%), functional outcomes (4%), natural history (4%), and standard of care (3%). One-hundred and three (36%) resulted in publications. Phase I human pharmaceutical trials are focusing on the safety of small molecule therapies (<jats:italic>n<\/jats:italic> = 8) and AAV and non-viral gene therapy (<jats:italic>n<\/jats:italic> = 3). Preclinical animal gene therapy studies include 11 different CMT forms including viral, CRISPR-Cas9, and nanoparticle delivery.<\/jats:p><\/jats:sec><jats:sec><jats:title>Conclusion<\/jats:title><jats:p>Current CMT trials are exploring procedural and molecular therapeutic options with substantial participation of the pharmaceutical industry worldwide. Emerging drug therapies directed at molecular pathogenesis are being advanced in human clinical trials; however, the majority remain within animal investigations.<\/jats:p><\/jats:sec>","DOI":"10.3389\/fneur.2023.1251885","type":"journal-article","created":{"date-parts":[[2023,9,22]],"date-time":"2023-09-22T12:33:23Z","timestamp":1695386003000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":5,"title":["Clinical trials in Charcot-Marie-Tooth disorders: a retrospective and preclinical assessment"],"prefix":"10.3389","volume":"14","author":[{"given":"Malavika A.","family":"Nair","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Zhiyv","family":"Niu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Nicholas N.","family":"Madigan","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Alexander Y.","family":"Shin","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jeffrey S.","family":"Brault","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Nathan P.","family":"Staff","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Christopher J.","family":"Klein","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"1965","published-online":{"date-parts":[[2023,9,22]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","first-page":"1224","DOI":"10.1212\/CON.0000000000000927","article-title":"Charcot-Marie-Tooth disease and other hereditary neuropathies","volume":"26","author":"Klein","year":"2020","journal-title":"Continuum."},{"key":"B2","doi-asserted-by":"publisher","first-page":"40","DOI":"10.1186\/s13023-018-0779-5","article-title":"Frequency of hereditary neuropathy with liability to pressure palsies (HNPP) due to 17p11. 2 deletion in a Korean newborn population","volume":"13","author":"Park","year":"2018","journal-title":"Orphanet J Rare Dis."},{"key":"B3","doi-asserted-by":"publisher","first-page":"922","DOI":"10.1212\/01.wnl.0000176062.44360.49","article-title":"Quality of life in patients with Charcot-Marie-Tooth disease","volume":"65","author":"Vinci","year":"2005","journal-title":"Neurology."},{"key":"B4","doi-asserted-by":"publisher","first-page":"644","DOI":"10.1038\/s41582-019-0254-5","article-title":"Next-generation sequencing in Charcot-Marie-Tooth disease: opportunities and challenges","volume":"15","author":"Pipis","year":"2019","journal-title":"Nat Rev Neurol."},{"key":"B5","doi-asserted-by":"publisher","first-page":"427","DOI":"10.1016\/j.nmd.2019.04.004","article-title":"Surgical outcomes of cavovarus foot deformity in children with Charcot-Marie-Tooth disease","volume":"29","author":"Lin","year":"2019","journal-title":"Neuromuscul Disord."},{"key":"B6","doi-asserted-by":"publisher","first-page":"834","DOI":"10.1001\/jamaneurol.2021.1272","article-title":"Five-year extension results of the phase 1 START trial of onasemnogene abeparvovec in spinal muscular atrophy","volume":"78","author":"Mendell","year":"2021","journal-title":"JAMA Neurol."},{"key":"B7","doi-asserted-by":"publisher","first-page":"82","DOI":"10.1056\/NEJMe1805499","article-title":"Oligonucleotide drugs for transthyretin amyloidosis","volume":"379","author":"Buxbaum","year":"2018","journal-title":"N Engl J Med."},{"key":"B8","doi-asserted-by":"publisher","first-page":"493","DOI":"10.1056\/NEJMoa2107454","article-title":"CRISPR-CAS9 in vivo gene editing for transthyretin amyloidosis","volume":"385","author":"Gillmore","year":"2021","journal-title":"N Engl J Med."},{"key":"B9","doi-asserted-by":"publisher","first-page":"372","DOI":"10.1016\/S0140-6736(21)02017-1","article-title":"Lentiviral haematopoietic stem-cell gene therapy for early-onset metachromatic leukodystrophy: long-term results from a non-randomised, open-label, phase 1\/2 trial and expanded access","volume":"399","author":"Fumagalli","year":"2022","journal-title":"Lancet."},{"key":"B10","doi-asserted-by":"publisher","first-page":"150","DOI":"10.1111\/jns.12543","article-title":"Charcot-Marie-Tooth neuropathies: current gene therapy advances and the route toward translation","volume":"28","author":"Stavrou","year":"2023","journal-title":"J Peripher Nerv Syst."},{"key":"B11","doi-asserted-by":"publisher","first-page":"294","DOI":"10.1084\/jem.20181040","article-title":"Gene therapy targeting SARM1 blocks pathological axon degeneration in mice","volume":"216","author":"Geisler","year":"2019","journal-title":"J Exp Med."},{"key":"B12","doi-asserted-by":"publisher","first-page":"5568","DOI":"10.1172\/JCI130600","article-title":"Allele-specific RNA interference prevents neuropathy in Charcot-Marie-Tooth disease type 2D mouse models","volume":"129","author":"Morelli","year":"2019","journal-title":"J Clin Invest."},{"key":"B13","doi-asserted-by":"publisher","first-page":"723023","DOI":"10.3389\/fcell.2021.723023","article-title":"Allele-specific gene editing rescues pathology in a human model of Charcot-Marie-Tooth disease type 2E","volume":"9","author":"Feliciano","year":"2021","journal-title":"Front Cell Dev Biol."},{"key":"B14","doi-asserted-by":"publisher","first-page":"855","DOI":"10.1038\/mt.2016.33","article-title":"Rescue of a mouse model of spinal muscular atrophy with respiratory distress type 1 by AAV9-IGHMBP2 is dose dependent","volume":"24","author":"Shababi","year":"2016","journal-title":"Mol Ther."},{"key":"B15","doi-asserted-by":"publisher","first-page":"659","DOI":"10.1038\/s41434-021-00250-0","article-title":"AAV9-mediated Schwann cell-targeted gene therapy rescues a model of demyelinating neuropathy","volume":"28","author":"Kagiava","year":"2021","journal-title":"Gene Ther."},{"key":"B16","doi-asserted-by":"publisher","first-page":"3528","DOI":"10.1093\/hmg\/ddz199","article-title":"Gene replacement therapy after neuropathy onset provides therapeutic benefit in a model of CMT1X","volume":"28","author":"Kagiava","year":"2019","journal-title":"Hum Mol Genet."},{"key":"B17","doi-asserted-by":"publisher","first-page":"1227","DOI":"10.1093\/brain\/awz064","article-title":"Gene replacement therapy in a model of Charcot-Marie-Tooth 4C neuropathy","volume":"142","author":"Schiza","year":"2019","journal-title":"Brain."},{"key":"B18","doi-asserted-by":"publisher","first-page":"159","DOI":"10.1172\/JCI137159","article-title":"AAV9-mediated FIG4 delivery prolongs life span in Charcot-Marie-Tooth disease type 4J mouse model","volume":"131","author":"Presa","year":"2021","journal-title":"J Clin Invest"},{"key":"B19","doi-asserted-by":"publisher","first-page":"1","DOI":"10.31083\/j.fbl2701001","article-title":"The protective role of mesencephalic astrocyte-derived neurotrophic factor in endoplasmic reticulum stress in RT4-D6P2T schwannoma sells with the S63del MPZ mutation","volume":"27","author":"Sun","year":"2022","journal-title":"Front Biosci."},{"key":"B20","doi-asserted-by":"publisher","first-page":"2356","DOI":"10.1038\/s41467-021-22593-3","article-title":"AAV2\/9-mediated silencing of PMP22 prevents the development of pathological features in a rat model of Charcot-Marie-Tooth disease 1 A","volume":"12","author":"Gautier","year":"2021","journal-title":"Nat Commun."},{"key":"B21","doi-asserted-by":"publisher","first-page":"13","DOI":"10.1172\/JCI159814","article-title":"A translatable RNAi-driven gene therapy silences PMP22\/Pmp22 genes and improves neuropathy in CMT1A mice","volume":"132","author":"Stavrou","year":"2022","journal-title":"J Clin Invest"},{"key":"B22","doi-asserted-by":"publisher","first-page":"568","DOI":"10.1007\/s00508-020-01785-9","article-title":"Effectiveness of focused extracorporeal shock wave therapy in the treatment of carpal tunnel syndrome : a randomized, placebo-controlled pilot study","volume":"133","author":"Gesslbauer","year":"2021","journal-title":"Wien Klin Wochenschr."},{"key":"B23","doi-asserted-by":"publisher","first-page":"317","DOI":"10.1038\/s42003-021-01839-2","article-title":"Squalenoyl siRNA PMP22 nanoparticles are effective in treating mouse models of Charcot-Marie-Tooth disease type 1 A","volume":"4","author":"Boutary","year":"2021","journal-title":"Commun Biol."},{"key":"B24","doi-asserted-by":"publisher","first-page":"130","DOI":"10.1093\/nar\/gkz1070","article-title":"Targeted PMP22 TATA-box editing by CRISPR\/Cas9 reduces demyelinating neuropathy of Charcot-Marie-Tooth disease type 1A in mice","volume":"48","author":"Lee","year":"2020","journal-title":"Nucleic Acids Res."},{"key":"B25","doi-asserted-by":"publisher","first-page":"359","DOI":"10.1172\/JCI96499","article-title":"PMP22 antisense oligonucleotides reverse Charcot-Marie-Tooth disease type 1A features in rodent models","volume":"128","author":"Zhao","year":"2018","journal-title":"J Clin Invest."},{"key":"B26","doi-asserted-by":"publisher","first-page":"511","DOI":"10.1038\/mt.2013.250","article-title":"AAV1. NT-3 gene therapy for Charcot-Marie-Tooth neuropathy","volume":"22","author":"Sahenk","year":"2014","journal-title":"Mol Ther."},{"key":"B27","doi-asserted-by":"publisher","first-page":"127","DOI":"10.1038\/s41434-021-00231-3","article-title":"AAV1. NT-3 gene therapy for X-linked Charcot-Marie-Tooth neuropathy type 1","volume":"29","author":"Ozes","year":"2022","journal-title":"Gene Ther."},{"key":"B28","doi-asserted-by":"publisher","first-page":"fcab252","DOI":"10.1093\/braincomms\/fcab252","article-title":"AAV1.NT-3 gene therapy in a CMT2D model: phenotypic improvements in Gars(P278KY\/+) mice","volume":"3","author":"Ozes","year":"2021","journal-title":"Brain Commun."},{"key":"B29","doi-asserted-by":"publisher","first-page":"4159","DOI":"10.1007\/s12035-022-02838-y","article-title":"Treatment with IFB-088 improves neuropathy in CMT1A and CMT1B Mice","volume":"59","author":"Bai","year":"2022","journal-title":"Mol Neurobiol."},{"key":"B30","doi-asserted-by":"publisher","first-page":"246","DOI":"10.1016\/j.freeradbiomed.2020.09.019","article-title":"Curcumin-cyclodextrin\/cellulose nanocrystals improve the phenotype of Charcot-Marie-Tooth-1A transgenic rats through the reduction of oxidative stress","volume":"161","author":"Caillaud","year":"2020","journal-title":"Free Radic Biol Med."},{"key":"B31","doi-asserted-by":"publisher","first-page":"113281","DOI":"10.1016\/j.expneurol.2020.113281","article-title":"HDAC6 inhibition promotes alpha-tubulin acetylation and ameliorates CMT2A peripheral neuropathy in mice","volume":"328","author":"Picci","year":"2020","journal-title":"Exp Neurol."},{"key":"B32","doi-asserted-by":"publisher","first-page":"146692","DOI":"10.1016\/j.brainres.2020.146692","article-title":"HDAC6 inhibitors: Translating genetic and molecular insights into a therapy for axonal CMT","volume":"1733","author":"Rossaert","year":"2020","journal-title":"Brain Res."},{"key":"B33","doi-asserted-by":"publisher","first-page":"e01118","DOI":"10.1002\/brb3.1118","article-title":"Efficacy of exogenous pyruvate in Trembler(J) mouse model of Charcot-Marie-Tooth neuropathy","volume":"8","author":"Sahenk","year":"2018","journal-title":"Brain Behav."},{"key":"B34","doi-asserted-by":"publisher","first-page":"479","DOI":"10.1002\/mus.27687","article-title":"Utility of carpal tunnel release and ulnar decompression in CMT1A and HNPP","volume":"66","author":"Chompoopong","year":"2022","journal-title":"Muscle Nerve."},{"key":"B35","doi-asserted-by":"publisher","first-page":"388","DOI":"10.1002\/mus.25742","article-title":"Carpal tunnel syndrome in inherited neuropathies: a retrospective survey","volume":"57","author":"Panosyan","year":"2018","journal-title":"Muscle Nerve."},{"key":"B36","doi-asserted-by":"publisher","first-page":"963849","DOI":"10.3389\/fneur.2022.963849","article-title":"Application of extracorporeal shock wave therapy in nervous system diseases: a review","volume":"13","author":"Guo","year":"2022","journal-title":"Front Neurol."},{"key":"B37","doi-asserted-by":"publisher","first-page":"584","DOI":"10.1302\/2058-5241.5.190067","article-title":"Extracorporeal shock wave therapy: an update","volume":"5","author":"Auersperg","year":"2020","journal-title":"EFORT Open Rev."},{"key":"B38","doi-asserted-by":"publisher","first-page":"851894","DOI":"10.3389\/fvets.2022.851894","article-title":"Biological response of extracorporeal shock wave therapy to tendinopathy in vivo (review)","volume":"9","author":"Chen","year":"2022","journal-title":"Front Vet Sci."},{"key":"B39","doi-asserted-by":"publisher","first-page":"2631","DOI":"10.2106\/JBJS.G.01356","article-title":"Long-term results of reconstruction for treatment of a flexible cavovarus foot in Charcot-Marie-Tooth disease","volume":"90","author":"Ward","year":"2008","journal-title":"J Bone Joint Surg Am."},{"key":"B40","doi-asserted-by":"publisher","first-page":"1138","DOI":"10.1016\/j.nmd.2017.09.005","article-title":"221st ENMC International workshop: foot surgery in Charcot-Marie-Tooth disease. 10-12 June 2016, Naarden, The Netherlands","volume":"27","author":"Reilly","year":"2017","journal-title":"Neuromuscul Disord."},{"key":"B41","doi-asserted-by":"publisher","first-page":"199","DOI":"10.1186\/s13023-014-0199-0","article-title":"An exploratory randomised double-blind and placebo-controlled phase 2 study of a combination of baclofen, naltrexone and sorbitol (PXT3003) in patients with Charcot-Marie-Tooth disease type 1A","volume":"9","author":"Attarian","year":"2014","journal-title":"Orphanet J Rare Dis."},{"key":"B42","doi-asserted-by":"publisher","first-page":"392","DOI":"10.1136\/jnnp-2012-303725","article-title":"Central nervous system abnormalities in patients with PMP22 gene mutations: a prospective study","volume":"84","author":"Chanson","year":"2013","journal-title":"J Neurol Neurosurg Psychiatry."},{"key":"B43","doi-asserted-by":"publisher","first-page":"433","DOI":"10.1186\/s13023-021-02040-8","article-title":"A double-blind, placebo-controlled, randomized trial of PXT3003 for the treatment of Charcot-Marie-Tooth type 1A","volume":"16","author":"Attarian","year":"2021","journal-title":"Orphanet J Rare Dis."}],"container-title":["Frontiers in Neurology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fneur.2023.1251885\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,9,22]],"date-time":"2023-09-22T12:33:26Z","timestamp":1695386006000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fneur.2023.1251885\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,9,22]]},"references-count":43,"alternative-id":["10.3389\/fneur.2023.1251885"],"URL":"https:\/\/doi.org\/10.3389\/fneur.2023.1251885","relation":{},"ISSN":["1664-2295"],"issn-type":[{"value":"1664-2295","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,9,22]]},"article-number":"1251885"}}